Evidence map›Paper›PMID 20211015›Full record

ArticleJournal of translational medicine2010

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.

Francesca M Rossi, Maria Ilaria Del Principe, Davide Rossi, Maria Irno Consalvo, Fabrizio Luciano, Antonella Zucchetto, Pietro Bulian, Riccardo Bomben, Michele Dal Bo, Marco Fangazio and 5 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Detection methods of ZAP-70 in chronic lymphocytic leukemia.Clinical and experimental medicine · 2012
    Review
  6. Combined normal donor and CLL: Single tube ZAP-70 analysis.Cytometry. Part B, Clinical cytometry · 2012
    Article
  7. Article
  8. Methodological comparison of two anti-ZAP-70 antibodies.Cytometry. Part B, Clinical cytometry · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francesca M RossiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy.
Maria Ilaria Del Principe
Davide Rossi
Maria Irno Consalvo
Fabrizio Luciano
Antonella Zucchetto
Pietro Bulian
Riccardo Bomben
Michele Dal Bo
Marco Fangazio
Dania Benedetti
Massimo Degan
Gianluca Gaidano
Giovanni Del Poeta
Valter Gattei

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundZAP-70 is an independent negative prognostic marker in chronic lymphocytic leukemia (CLL). Usually, its expression is investigated by flow cytometric protocols in which the percentage of ZAP-70 positive CLL cells is determined in respect to isotypic control (ISO-method) or residual ZAP-70 positive T cells (T-method). These methods, however, beside suffering of an inherent subjectivity in their application, may give discordant results in some cases. The aim of this study was to assess the prognostic significance of these methods in comparison with another in which ZAP-70 expression was evaluated as a Mean-Fluorescence-Intensity Ratio between gated T and CLL cells (T/B Ratio-method).

methodsCytometric files relative to ZAP-70 determination according to the three readouts were retrospectively reviewed on a cohort of 173 patients (test set), all with complete clinical and biological prognostic assessment and time-to-treatment (TTT) available. Findings were then validated in an independent cohort of 341 cases from a different institution (validation set).

resultsThe optimal prognostic cut-offs for ZAP-70 expression were selected at 11% (ISO-method) or 20% of positive cells (T-method), as well as at 3.0 (T/B Ratio-method) in the test set; these cut-offs yielded 66, 60 and 73 ZAP-70+ cases, respectively. Univariate analyses resulted in a better separation of ZAP-70+ vs. ZAP-70- CLL patients utilizing the T/B Ratio, compared to T- or ISO-methods. In multivariate analyses which included the major clinical and biological prognostic markers for CLL, the prognostic impact of ZAP-70 appeared stronger when the T/B-Ratio method was applied. These findings were confirmed in the validation set, in which ZAP-70 expression, evaluated by the T- (cut-off = 20%) or T/B Ratio- (cut-off = 3.0) methods, yielded 180 or 127 ZAP-70+ cases, respectively. ZAP-70+ patients according to the T/B Ratio-method had shorter TTT, both if compared to ZAP-70- CLL, and to cases classified ZAP-70+ by the T-method only.

conclusionsWe suggest to evaluate ZAP-70 expression in routine settings using the T/B Ratio-method, given the operator and laboratory independent feature of this approach. We propose the 3.0 T/B Ratio value as optimal cut-off to discriminate ZAP-70+ (T/B Ratio less than 3.0) from ZAP-70- (T/B Ratio more/equal than 3.0) cases.

Indexed as

B-LymphocytesLeukemia, Lymphocytic, Chronic, B-CellLymphocyte SubsetsT-LymphocytesAdultAgedAged, 80 and overBiomarkers, TumorFemaleFlow CytometryHumansImmunoglobulin Heavy ChainsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisBiomarkers, TumorImmunoglobulin Heavy ChainsZAP70 protein, humanZAP-70 Protein-Tyrosine Kinase

Identifiers

PMID20211015
PMCPMC2846891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.